LAB

SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · nonDerivative · entry 3

Cox Troy · CIK 0001696923 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 198,104

F3 · shares: Represents RSUs that vest in four equal annual installments beginning March 17, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

F4 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of SomaLogic common stock (a "SomaLogic RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of common stock of the Company equal to the to the product of (i) the number of shares subject to such SomaLogic RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Company common stock rounded to the next nearest whole share. Except as noted above, each assumed SomaLogic RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic RSU immediately prior to the Effective Time.

SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · nonDerivative · entry 2

Cox Troy · CIK 0001696923 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 166,469

F2 · shares: Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning January 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

SEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · nonDerivative · entry 1

Cox Troy · CIK 0001696923 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,057

F1 · shares: Received in exchange for 78,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time").

F1 · price: Received in exchange for 78,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time").

SEC source: 0001104659-24-002652 · tm242400-5_4seq1.xml · derivative · entry 2

Carey Thomas D. · CIK 0001574633 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,794

Underlying: Common Stock · 205,794 shares

Expires 2033-06-07

F3 · price: Pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic, Inc. ("Soma Logic") (the "Merger"), each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 (the "Exchange Ratio") rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent.

F4 · price: Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time.

F2 · derivative.exercise_date: 25% of the shares underlying the option vest on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is fully vested, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001104659-24-002652 · tm242400-5_4seq1.xml · nonDerivative · entry 1

Carey Thomas D. · CIK 0001574633 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,412

F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning January 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

SEC source: 0001104659-24-002651 · tm242400d4_4seq1.xml · derivative · entry 2

HIBBS KATHY L · CIK 0001267487 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 205,794

Underlying: Common Stock · 205,794 shares

Expires 2033-06-07

F3 · price: Pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic, Inc. ("Soma Logic") (the "Merger"), each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the Merger (the "Effective Time"), was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) 1.11 (the "Exchange Ratio") rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent.

F4 · price: Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time.

F2 · derivative.exercise_date: 25% of the shares underlying the option vest on June 8, 2024, and thereafter 1/36th of the total grant vests monthly until such time as the option is fully vested, subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001104659-24-002651 · tm242400d4_4seq1.xml · nonDerivative · entry 1

HIBBS KATHY L · CIK 0001267487 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,412

F1 · shares: Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning January 5, 2025, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting.

SEC source: 0000950170-24-042373 · ownership.xml · nonDerivative · entry 1

Egholm Michael · CIK 0001559779 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,518

F1 · shares: Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger.

SEC source: 0000950170-23-054492 · ownership.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,111

F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest 100% on December 15, 2023. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control.

F2 · price: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $4,000 in cash compensation for services as a committee memeber. The share price is based on the Fair Market Value as of the first date of quarterly trading window following the date on which the Reporting Person's new committe assignment was approved by the Board.

F3 · balance_after: Represents Restricted Stock Units with respect to which the Reporting Person has deferred settlement as described above.

SEC source: 0000902664-23-003816 · ownership.xml · nonDerivative · entry 2

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 7,797,454

F1 · kind: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.

F3 · price: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager.

F3 · balance_after: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager.

F2 · ownership.nature: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

SEC source: 0000902664-23-003816 · ownership.xml · nonDerivative · entry 1

Caligan Partners LP · CIK 0001727492 · 10% owner

JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 8,467,920

F1 · price: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.

F2 · ownership.nature: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.

SEC source: 0001162194-23-000050 · wk-form4_1686963030.xml · derivative · entry 2

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,380

Underlying: Common Stock · 35,380 shares

Expires 2033-06-14

F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000050 · wk-form4_1686963030.xml · nonDerivative · entry 1

Madaus Martin D · CIK 0001310268 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,537

F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000044 · wk-form4_1686962679.xml · derivative · entry 2

Paya Carlos V · CIK 0001606244 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,380

Underlying: Common Stock · 35,380 shares

Expires 2033-06-14

F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000044 · wk-form4_1686962679.xml · nonDerivative · entry 1

Paya Carlos V · CIK 0001606244 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 126,844

F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000048 · wk-form4_1686962930.xml · derivative · entry 3

Casdin Eli · CIK 0001534264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,380

Underlying: Common Stock · 35,380 shares

Expires 2033-06-14

F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000048 · wk-form4_1686962930.xml · nonDerivative · entry 1

Casdin Eli · CIK 0001534264 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,142

F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000046 · wk-form4_1686962794.xml · derivative · entry 3

Witney Frank · CIK 0001455312 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,380

Underlying: Common Stock · 35,380 shares

Expires 2033-06-14

F3 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000046 · wk-form4_1686962794.xml · nonDerivative · entry 1

Witney Frank · CIK 0001455312 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,142

F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000041 · wk-form4_1686962510.xml · derivative · entry 2

Clague Laura · CIK 0001388773 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,380

Underlying: Common Stock · 35,380 shares

Expires 2033-06-14

F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000041 · wk-form4_1686962510.xml · nonDerivative · entry 1

Clague Laura · CIK 0001388773 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,791

F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000039 · wk-form4_1686962359.xml · derivative · entry 2

ELOI FENEL M · CIK 0001237190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,380

Underlying: Common Stock · 35,380 shares

Expires 2033-06-14

F2 · derivative.exercise_date: The Option becomes exercisable in twelve equal monthly increments beginning on July 14, 2023 subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0001162194-23-000039 · wk-form4_1686962359.xml · nonDerivative · entry 1

ELOI FENEL M · CIK 0001237190 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 98,463

F1 · shares: Consists of Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of common stock upon vesting. The Restricted Stock Units vest in full on the earlier to occur of June 14, 2024 and one day prior to the date of the Company's next annual meeting of stockholders subject to the Reporting Person's continued service through the applicable vesting date.

SEC source: 0000919574-23-003426 · ownership.xml · nonDerivative · entry 3

Casdin Eli · CIK 0001534264 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,200,000

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.29 to $2.2982. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0000919574-23-003425 · ownership.xml · nonDerivative · entry 3

Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner

Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner

Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director

Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director

Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,200,000

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.29 to $2.2982. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0001162194-23-000030 · wf-form4_168479578184518.xml · nonDerivative · entry 2

Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,984

F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.23 to $2.32. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0000919574-23-003426 · ownership.xml · nonDerivative · entry 2

Casdin Eli · CIK 0001534264 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 400,000

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.1489 to $2.1759. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0000919574-23-003425 · ownership.xml · nonDerivative · entry 2

Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner

Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner

Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director

Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director

Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 400,000

F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.1489 to $2.1759. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0001162194-23-000030 · wf-form4_168479578184518.xml · nonDerivative · entry 1

Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,492

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.14 to $2.28. Full information regarding the number of shares purchased at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

SEC source: 0000919574-23-003426 · ownership.xml · nonDerivative · entry 1

Casdin Eli · CIK 0001534264 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 250,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $1.855 to $1.9237. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0000919574-23-003425 · ownership.xml · nonDerivative · entry 1

Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner

Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner

Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner

Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director

Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director

Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 250,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $1.855 to $1.9237. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

F2 · ownership.nature: The securities are owned directly by Casdin Partners FO1-MSV, LP ("Casdin FO1") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin FO1, (ii) Casdin Partners GP, LLC, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.

SEC source: 0001162194-23-000028 · wf-form4_168437220935635.xml · derivative · entry 2

Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2033-05-15

F3 · derivative.exercise_date: The Option becomes exercisable as to 1/4th of the underlying shares on May 15, 2024, and as to an additional 1/48th of the total number of shares each month thereafter, subject to Mr. Black's continued service through the applicable vesting date.

SEC source: 0001162194-23-000028 · wf-form4_168437220935635.xml · derivative · entry 1

Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,526

Underlying: Common Stock · 210,526 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F2 · derivative.exercise_date: Restricted Stock Units vest as to 1/4 of the underlying shares on May 15, 2024, and as to an additional 1/16th of the total number of shares every three months thereafter, subject to Mr. Black's continued service through the applicable vesting date.

F2 · derivative.expiration_date: Restricted Stock Units vest as to 1/4 of the underlying shares on May 15, 2024, and as to an additional 1/16th of the total number of shares every three months thereafter, subject to Mr. Black's continued service through the applicable vesting date.

SEC source: 0001162194-23-000021 · wf-form4_168082231753896.xml · derivative · entry 2

Kim Hanjoon Alex · CIK 0001919209 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,549

Underlying: Common Stock · 70,183 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F2 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023.

F2 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023.

SEC source: 0001162194-23-000021 · wf-form4_168082231753896.xml · nonDerivative · entry 1

Kim Hanjoon Alex · CIK 0001919209 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,183

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001162194-23-000019 · wf-form4_168082215819281.xml · derivative · entry 2

Egholm Michael · CIK 0001559779 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 589,537

Underlying: Common Stock · 196,512 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments beginning April 4, 2023.

SEC source: 0001162194-23-000019 · wf-form4_168082215819281.xml · nonDerivative · entry 1

Egholm Michael · CIK 0001559779 · Director · President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 206,512

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 5,000 shares of Common Stock purchased pursuant to Fluidigm Corporation (currently Standard BioTools Inc.) 2017 Employee Stock Purchase Plan ("ESPP") for the purchase period of June 1, 2022 to November 30, 2022.

SEC source: 0001162194-23-000017 · wf-form4_167908754662266.xml · nonDerivative · entry 1

ELOI FENEL M · CIK 0001237190 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,087

F1 · shares: Represents Restricted Stock Units that vest in four equal annual installments beginning March 15, 2024.

SEC source: 0001162194-23-000010 · wf-form4_167720668432890.xml · derivative · entry 3

Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 229,167

Underlying: Common Stock · 20,833 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F2 · derivative.exercise_date: On December 20, 2022, the Reporting Person was granted 250,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023.

F2 · derivative.expiration_date: On December 20, 2022, the Reporting Person was granted 250,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023.

SEC source: 0001162194-23-000010 · wf-form4_167720668432890.xml · nonDerivative · entry 2

Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,657

SEC source: 0001162194-23-000010 · wf-form4_167720668432890.xml · nonDerivative · entry 1

Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,833

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · derivative · entry 12

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,176

Underlying: Common Stock · 3,130 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F7 · derivative.exercise_date: On April 20, 2021, the Reporting Person was granted 50,089 Restricted Stock Units vesting as to 1/4 of the total number of shares on May 20, 2022, and as to 1/16th of the total number of shares each quarter thereafter.

F7 · derivative.expiration_date: On April 20, 2021, the Reporting Person was granted 50,089 Restricted Stock Units vesting as to 1/4 of the total number of shares on May 20, 2022, and as to 1/16th of the total number of shares each quarter thereafter.

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · derivative · entry 11

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,563

Underlying: Common Stock · 2,391 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F6 · derivative.exercise_date: On March 10, 2020, the Reporting Person was granted 38,250 Restricted Stock Units vesting as to 1/4th of the underlying shares on February 20, 2021, and as to 1/16th of the total number of shares each quarter thereafter.

F6 · derivative.expiration_date: On March 10, 2020, the Reporting Person was granted 38,250 Restricted Stock Units vesting as to 1/4th of the underlying shares on February 20, 2021, and as to 1/16th of the total number of shares each quarter thereafter.

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · derivative · entry 10

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,238 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F5 · derivative.exercise_date: On February 19, 2019, the Reporting Person was granted 35,787 Restricted Stock Units vesting as to 1/4th of the total number of shares on February 20, 2020, and as to 1/16th of the total number of shares each quarter thereafter.

F5 · derivative.expiration_date: On February 19, 2019, the Reporting Person was granted 35,787 Restricted Stock Units vesting as to 1/4th of the total number of shares on February 20, 2020, and as to 1/16th of the total number of shares each quarter thereafter.

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · derivative · entry 9

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 183,334

Underlying: Common Stock · 16,666 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F4 · derivative.exercise_date: On December 20, 2022, the Reporting Person was granted 200,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023.

F4 · derivative.expiration_date: On December 20, 2022, the Reporting Person was granted 200,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023.

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · derivative · entry 8

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.

F3 · derivative.exercise_date: The Restricted Stock Units vest in full on February 20, 2023 or the date the Reporting Person's employment with the Company is terminated involuntarily without "cause."

F3 · derivative.expiration_date: The Restricted Stock Units vest in full on February 20, 2023 or the date the Reporting Person's employment with the Company is terminated involuntarily without "cause."

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · nonDerivative · entry 6

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,622

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · nonDerivative · entry 5

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 246,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · nonDerivative · entry 4

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 243,199

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001162194-23-000008 · wf-form4_167720307303910.xml · nonDerivative · entry 3

JOG VIKRAM · CIK 0001222641 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 240,808

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.